Amendments to the Claims

1. (currently amended) A compound of Formula (I)



(I)

or pharmaceutically acceptable salt ~~or solvate~~ thereof,

wherein

B is CH or N;

D is CH_2 or NH;

R^1 is selected from the group consisting of H, -CN, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy and $N(C_{1-4}$ alkyl$)_2$ optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C_{1-4} haloalkyl and C_{1-4} alkoxy;

R^2 is selected from the group consisting of H, halo, -CN, hydroxy, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$, $-C_{1-6}alkylNR^4R^6$, $-C_{1-6}alkylOR^6$, CO_2R^6, O_2CR^6, COR^6, CON^4R^6, $NR^4CO_2R^6$, $NR^4SO_2R^6$, NR^4COR^6, $OCONR^4R^6$ and $NR^4CONR^5R^6$;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting

of -CN, hydroxy, halo, C_{1-4} haloalkyl, C_{1-4} alkoxy, CO_2C_{1-4} alkyl or phenyl; or

R^2 is morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, C_{1-4} alkoxy- C_{1-4} alkyl, C_{3-6} cycloalkyl, $-OR^4$, halo, C_{1-4} haloalkyl, -CN, SH, $-S(O)_2R^5$, $-COR^4$, $-CO_2R^4$, $-OC(O)R^5$, $-N(COR^4)_2$, $-NR^4R^7$ and $-CONR^4R^7$, $-NR^4COR^5$, $NR^4SO_2R^5$, $NR^4CONR^5R^7$ or $NR^4CO_2R^5$;

R^3 is selected from the group consisting of H, halo, -CN, hydroxy, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$, $-C_{1-6}alkylNR^4R^6$, $-C_{1-6}alkylOR^6$, CO_2R^6, O_2CR^6, COR^6, CON^4R^6, $NR^4CO_2R^6$, $NR^4SO_2R^6$, NR^4COR^6, $OCONR^4R^6$, and $NR^4CONR^5R^6$;

optionally and independently substituted with 1 to 3 substituents selected from the group consisting of -CN, hydroxy, halo, C_{1-4} haloalkyl, C_{1-4} alkoxy, CO_2C_{1-4} alkyl, phenyl or naphthl; or

R^3 is morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, phenyl, pyridyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl,

pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl and indazolyl, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy- C_{1-4} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl, -CN, SH, $-S(O)_2R^5$, $-COR^4$, $-CO_2R^4$, $-OC(O)R^5$, $-N(COR^4)_2$, $-NR^4R^7$ and $-CONR^4R^7$, $-NR^4COR^5$, $NR^4SO_2R^5$, $NR^4CONR^5R^7$ or $NR^4CO_2R^5$;

Ar is selected from the group consisting of phenyl, indanyl, indenyl, pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, pyrrolidinyl, dihydroimidazolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, independently and optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy- C_{1-4} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl, -CN, $-NO_2$, SH, $-S(O)_2R^5$, $-COR^4$, $-CO_2R^4$, $-OC(O)R^5$, $-N(COR^4)_2$, $-NR^4R^7$ and $-CONR^4R^7$, $-NR^4COR^5$, $NR^4SO_2R^5$, $NR^4CONR^5R^7$, and $NR^4CO_2R^5$;

R^4, R^5 and R^7 are independently selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl-C_{3-6} alkyl, C_{1-2} alkoxy-C_{1-4} alkyl and C_{1-4} haloalkyl; and

R^6 is selected from the group consisting of H, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl-C_{1-6} alkyl, C_{1-2} alkoxy-C_{1-2} alkyl, C_{1-4} haloalkyl, phenyl and C_{1-6} alkyl-phenyl.

2. (original) A compound according to claim 1 wherein B is CH.

3. (original) A compound according to claim 1 wherein B is CH and D is CH_2.

4. (original) A compound according to claim 1 wherein B is CH and D is NH.

5. (original) A compound according to claim 1 wherein R^1 is C_{1-4} alkyl.

6. (original) A compound according to claim 1 wherein R^2 is H or substituted or unsubsituted C_{1-6}alkyl, morpholinyl, piperazinyl or phenyl.

7. (original) A compound according to claim 1 wherein R^3 is H, halo, CN or hydroxy, substituted or unsubstituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$ or O_2CR^6.

8. (original) A compound according to claim 1 wherein R^3 is pyrimidinyl and pyridinyl.

9. (original) A compound according to claim 1 wherein Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl,

-CN, $-NO_2$ or $-CO_2R^4$.

10. (original) A compound according to claim 1 wherein R^4 , R^5 and R^7 are independently H or C_{1-6} alkyl.

11. (original) A compound according to claim 1 wherein R^6 is H.

12. (original) A compound according to claim 1 wherein R^1 is C_{1-4} alkyl; R^2 is H or substituted or unsubsituted C_{1-6}alkyl, morpholinyl, piperazinyl or phenyl; R^3 is H, halo, CN or hydroxy, substituted or unsubstituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$ or O_2CR^6 ; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl, -CN, $-NO_2$ or $-CO_2R^4$; R^4 , R^5 and R^7 are independently H or C_{1-6} alkyl; and R^6 is H.

13. (original) A compound according to claim 1 wherein B is CH; R^1 is C_{1-4} alkyl; R^2 is H or substituted or unsubsituted C_{1-6}alkyl, morpholinyl, piperazinyl or phenyl; R^3 is H, halo, CN or hydroxy, substituted or unsubstituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-NR^4R^6$ or O_2CR^6 ; Ar is phenyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, pyrrolidinyl, dihydroimidazolyl optionally substituted with 1 to 4 substituents selected from the group consisting of H, C_{1-6} alkyl, $-OR^4$, halo, C_{1-4} haloalkyl, -CN, $-NO_2$ or $-CO_2R^4$; R^4 , R^5 and R^7 are independently H or C_{1-6} alkyl; and R^6 is H.

14. (original) [5-(4-Methoxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-

trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenol; Acetic acid 4-[2-methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-phenyl ester; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(4-methoxy-2-methylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(6-methoxy-2-methylpyridin-3-yl)-amine; [5-(3-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(3-Benzyloxybenzenesulfonyl)-2-methoxypyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; 5-(3-Benzyloxybenzenesulfonyl)-N^2,N^2-dimethyl-N^4-(2,4,6-trimethylphenyl)-pyrimidine-2,4-diamine; {5-[4-(2-Methoxybenzyloxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; {5-[4-(3,5-Dimethoxybenzyloxy)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzyloxybenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4-dimethoxyphenyl)-amine; 5-(4-Methoxyoxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; 5-(4-Benzyloxybenzenesulfonyl)-2-methyl-4-(2,4,6-trimethylbenzyl)-pyrimidine; [5-(4-Fluorobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-morpholin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {2-Methyl-5-[4-(4-methylpiperazin-1-yl)-benzenesulfonyl]-pyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; [5-(4-Imidazol-1-yl-benzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrrolidin-1-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [5-(4-Benzylaminobenzenesulfonyl)-2-methylpyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {5-[4-(Benzylmethylamino)-benzenesulfonyl]-2-methylpyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; 4-[2-Methyl-4-(2,4,6-trimethylphenylamino)-pyrimidine-5-sulfonyl]-benzonitrile; [2-

Methyl-5-(toluene-4-sulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-5-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyrimidin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-4-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-2-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; [2-Methyl-5-(4-pyridin-3-yl-benzenesulfonyl)-pyrimidin-4-yl]-(2,4,6-trimethylphenyl)-amine; {5-[4-(4,5-Dihydro-1H-imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine; or {5-[4-(1H-Imidazol-2-yl)-benzenesulfonyl]-2-methyl-pyrimidin-4-yl}-(2,4,6-trimethylphenyl)-amine or pharmaceutically acceptable salts or solvates thereof.

15. (currently amended) A pharmaceutical composition comprising ~~of a~~ a compound according to claim 1 and a pharmaceutically acceptable carrier.

16. (currently amended) A method of treating depression or anxiety comprising the administration of a compound of claim 15.